SCHEMBL21987446

SCHEMBL21987446

CC(C)(C)OC(=O)N1CCC(C(=O)O)CC1CO[Si](c1ccccc1)(c1ccccc1)C(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STS P08842 1/20 0.39
HSD17B10 Q99714 1/20 0.39
GPR119 Q8TDV5 1/20 0.37
KDM4E B2RXH2 1/20 0.36
PKM P14618 1/20 0.36
NR1H2 P55055 2/20 0.36
NR1H3 Q13133 2/20 0.36
PARP1 P09874 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
TSHR P16473 2/20 0.35
MAPK1 P28482 1/20 0.35
HCRTR2 O43614 1/20 0.35
USP30 Q70CQ3 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21987444 1.00 STS (0.39) STSHSD17B10GPR119KDM4EPKM
SCHEMBL21987443 1.00 STS (0.39) STSHSD17B10GPR119KDM4EPKM
SCHEMBL25568114 0.89 GPR119 (0.38) STSGPR119KDM4EPKMNR1H2
SCHEMBL25568115 0.89 GPR119 (0.38) STSGPR119KDM4EPKMNR1H2
SCHEMBL31122948 0.89 GPR119 (0.38) STSGPR119KDM4EPKMNR1H2
SCHEMBL25568112 0.89 GPR119 (0.38) STSGPR119KDM4EPKMNR1H2
SCHEMBL25568127 0.88 TACR1 (0.40) STSGPR119KDM4EPKMNR1H2
SCHEMBL25568111 0.88 TACR1 (0.40) STSGPR119KDM4EPKMNR1H2
SCHEMBL21987812 0.87 KDM4E (0.40) STSGPR119KDM4EPKMNR1H2
SCHEMBL21987810 0.87 KDM4E (0.40) STSGPR119KDM4EPKMNR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11639350-B2 Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections JANSSEN PHARMACEUTICA NV (BE) 2023-05-02 US disclosed
US-20200172532-A1 HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS JANSSEN PHARMACEUTICA NV (BE) 2020-06-04 US disclosed
CN-110809574-A Heteroaryl dihydropyrimidine derivatives and methods for treating hepatitis b infection 詹森药业有限公司 2020-02-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200172532-A1 HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS HAVCR2, HCCS, PYGL STS 3540/4885HSD17B10 461/4885GPR119 3102/4885
US-11639350-B2 Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections HCCS, HAVCR2, NR1H4 STS 2021/4885HSD17B10 166/4885GPR119 3009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.